Yasuyuki Ikezawa

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Venues

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis. Cancer medicine 13 (14) (2024)
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis. Cancer medicine 13 (14) (2024)
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Toshiyuki Sumi, Hajime Kikuchi, Yasuo Kitamura, Atsushi Nakamura, Maki Kobayashi, Mari Aso, Nozomu Kimura, Fumiaki Yoshiike, Furuta Megumi, Hisashi Tanaka, Motoki Sekikawa, Tsutomu Hachiya, Keiichi Nakamura, Fumihiro Hommura, Noriaki Sukoh, Kenichiro Ito, Takashi Kikuchi, Toshihiko Agatsuma, Hiroshi Yokouchi
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis. Cancer medicine 13 (14) (2024)

Yasuyuki Ikezawa.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yasuyuki Ikezawa